Nuwellis closes $6M public offering to fund growth in cardiorenal medical tech.

Nuwellis, Inc., a medical technology company focused on cardiorenal conditions, has closed a public offering raising approximately $6 million. The offering included common stock and warrants, priced around $0.30 per share and warrant. Proceeds will support the company's development and commercialization efforts for its cardiorenal treatment technologies. The offering was managed by Ladenburg Thalmann & Co. and is part of Nuwellis' strategy to expand its market presence and product portfolio in 2026 and beyond.